- Home
- MBBC vs INMB Comparison
MBBC vs INMB Comparison
Compare MBBC & INMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MBBC | INMB |
|---|---|---|
| Founded | 1902 | 2015 |
| Country | United States | United States |
| Employees | 35 | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.2M | 37.2M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | MBBC | INMB |
|---|---|---|
| Price | $14.02 | $1.25 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $5.40 |
| AVG Volume (30 Days) | 18.3K | ★ 462.5K |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 11.85 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $50,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $47.11 | ★ N/A |
| Revenue Growth | N/A | ★ 257.14 |
| 52 Week Low | $9.95 | $1.09 |
| 52 Week High | $15.75 | $11.64 |
Technical Indicators
Market Signals| Indicator | MBBC | INMB |
|---|---|---|
| Relative Strength Index (RSI) | 54.56 | 39.01 |
| Support Level | $12.90 | $1.15 |
| Resistance Level | $15.57 | $1.48 |
| Average True Range (ATR) | 0.54 | 0.09 |
| MACD | 0.02 | -0.02 |
| Stochastic Oscillator | 77.72 | 1.56 |
Price Performance
Historical ComparisonAbout MBBC Marathon Bancorp Inc.
Marathon Bancorp Inc is a mid-tier holding company for Marathon Bank, a Wisconsin-chartered savings bank. The group operates as a community-oriented bank offering a variety of financial products and services to meet the needs of customers. The primary deposit products are demand deposits, savings, and certificates of deposits; and prime lending products are commercial real estate, commercial and industrial, construction, one-to-four-family residential, multifamily real estate, and consumer loans. The majority of the group's revenue comes from interest income on loans and debt securities.
About INMB INmune Bio Inc.
INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease. The company's pipeline products include INKmune, XPro1595, and others. It has three product platforms; The CORDStrom product platform, The DN-TNF product platform, and The Natural Killer Cell Priming Platform.